Acorda halts enrollment in Parkinson's disease trial

(Reuters) - Acorda Therapeutics Inc said on Wednesday it has halted enrolling patients in a late-stage trial testing its drug to treat Parkinson's disease, after reports of cases related to neutropenia, sepsis and death.